Main Article Content
Diabetes mellitus (DM) is considered a 21st century pandemic and is often associated with cardiovascular disease (CVD). The aim of this integrative review was to analyze the cardioprotective effects of phosdodiesterase-5 (PDE5i) inhibitors in experimental diabetes models. The articles were selected from the PubMed, SciElo and LILACS databases from 2014 to 2019. The following descriptors were used in combination with the Boolean operators: Diabetes mellitus experimental AND Phosphodiesterase 5 inhibitors; Diabetic cardiomyopathies AND Phosphodiesterase 5 inhibitors. An initial sample of 155 articles was obtained, of which six met the criteria for the synthesis of the review. The studies analyzed showed that treatment with PDE5i in experimental models, resulted in positive effects on cardiac function and metabolic parameters. Similar results have also been seen in humans. The reduction in cardiac hypertrophy, apoptosis of cardiomyocytes, pro-inflammatory factors and oxidative stress and the modulation of transcription factors involved in diabetes homeostasis, were prevalent among studies. The mechanisms of action involved in cardioprotection have not yet been fully elucidated, however the restoration of the activated cyclic guanosine monofate (cGMP) pathway by soluble guanylate cyclase (sGC) via nitric oxide (NO) was a common mechanism among the studies.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
2. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2012;17(3):325-44. http://dx.doi.org/10.1007/s10741-011-9257-z
3. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660-71. http://dx.doi.org/10.1007/s00125-014-3171-6
4. Gilca GE, Stefanescu G, Badulescu O, Tanase DM, Bararu I, Ciocoiu M. Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets. J Diabetes Res. 2017;2017:1-7. http://doi.org/10.1155/2017/1310265
5. Tian J, Zhao Y, Liu Y, Liu Y, Chen K, Lyu S. Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective. Oxid Med Cell Longev. 2017;2017:8214541. http://doi.org/10.1155/2017/8214541
6. Carabetti JAM. Cardiomiopatía diabética. Rev Urug Cardiol. 2017;32(3):264-76. http://dx.doi.org/10.29277/RUC/32.3.7
7. Lukowski R, Krieg T, Rybalkin SD, Beavo J, Hofmann F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: Boom, bust, and beyond. Trends Pharmacol Sci. 2014;35(8):404-13. http://dx.doi.org/10.1016/j.tips.2014.05.003
8. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al. Oxidative stress regulates left ventricular PDE5 expression in the falling heart. Circulation. 2010;121(3):1474-8. http://doi.org/10.1161/circulationaha.109.906818
9. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12-21. http://doi.org/10.1016/j.pharmthera.2014.10.003
10. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem. 2003;278(48):47694-9. http://doi.org/10.1074/jbc.m309661200
11. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci. 2001;98(5):2703-6. http://doi.org/10.1073/pnas.051625598
12. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol. 2000;184(3):409-20. http://doi.org/10.1002/1097-4652(200009)184:33.0.co;2-k
13. Polsinelli VB, Shah SJ. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother. 2017;18(4):399-409. http://doi.org/10.1080/14656566.2017.1288717
14. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797-811. http://doi.org/10.1093/eurheartj/ehu204
15. Frey MK, Lang I. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2012;13(5):747-55. http://doi.org/10.1517/14656566.2012.662220
16. Melnyk BM, Fineout-Overholt E. Making the case for evidence-based practice and cultivating a spirit of inquiry. In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare. A guide to best practice. 2nd ed. Philadelphia: Wolters Kluwer, 2011; p.3-24.
17. Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(2):546-53. http://doi.org/10.1111/j.1365-2648.2005.03621.x
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;7(6):e1000097. http://doi.org/10.1371/journal.pmed.1000097
19. Bacci L, Barbati SA, Colussi C, Aiello A, Isidori AM, Grassi C, et al. Sildenafil normalizes MALAT1 level in diabetic cardiomyopathy. Endocrine. 2018;62(1):259-62. http://doi.org/10.1007/s12020-018-1599-z
20. Barbati SA, Colussi C, Bacci L, Aiello A, Re A, Stigliano E, et al. Transcription factor CREM mediates high glucose response in cardiomyocytes and in a male mouse model of prolonged hyperglycemia. Endocrinology. 2017;158(7):2391-405. http://doi.org/10.1210/en.2016-1960
21. Venneri MA, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R, et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One. 2015;10(5):e0126580. http://doi.org/10.1371/journal.pone.0126580
22. Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. Am J Physiol Circ Physiol. 2014;306(11):1558-68. http://doi.org/10.1152/ajpheart.00865.2013
23. Goulopoulou S, Hannan JL, Matsumoto T, Ogbi S, Ergul A, Webb RC. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Am J Physiol Circ Physiol. 2015;309(2):H297. http://doi.org/10.1152/ajpheart.00079.2015
24. Mátyás C, Németh BT, Oláh A, Török M, Ruppert M, Kellermayer D, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail. 2017;19(3):326-36. http://doi.org/10.1002/ejhf.711
25. Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC. Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One. 2012;7(9):e45243. http://doi.org/e45243.10.1371/journal.pone.0045243
26. Koka S, Xi L, Kukreja RC. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol. 2012;107(2):249. http://doi.org/10.1007/s00395-012-0249-5
27. Koka S, Das A, Salloum FN, Kukreja RC. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med. 2013;60:80-8. http://doi.org/10.1016/j.freeradbiomed.2013.01.031
28. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125(19):2323-33. http://doi:10.1161/CIRCULATIONAHA.111.063412